Advaxis to Host Business Update Conference Call on June 11, 2019
June 04 2019 - 8:00AM
Business Wire
Advaxis, Inc. (NASDAQ: ADXS), a late-stage
biotechnology company focused on the discovery, development and
commercialization of immunotherapy products, announces that the
company will host a business update call on Tuesday, June 11, 2019
at 11:00 a.m. ET.
During the call, Advaxis’ senior management will review the
company’s clinical development programs and recent financial
results, and provide a general business update. The company intends
to issue a news release summarizing financial results for the
fiscal second quarter ended April 30, 2019 after market close on
Monday, June 10, 2019.
The conference call and live audio webcast information is as
follows:
WHEN: Tuesday, June 11, 2019 at 11:00 a.m. ETDOMESTIC DIAL-IN:
(844) 348-6133INTERNATIONAL DIAL-IN: (631) 485-4564CONFERENCE ID:
6199489WEBCAST: ir.advaxis.com/events-presentations
For those unable to participate in the live conference call or
webcast, a digital recording will be available beginning June 11,
2019 two hours after the completion of the call. To access the
recording, please dial (855) 859-2056 (domestic) or (404) 537-3406
(international) and provide the operator with the conference ID:
6199489. In addition, an audio webcast will be archived on the
Company’s website for a period of time at www.advaxis.com.
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on
the discovery, development and commercialization of
proprietary Lm-based antigen delivery products. These
immunotherapies are based on a platform technology that utilizes
live attenuated Listeria monocytogenes (Lm) bioengineered to
secrete antigen/adjuvant fusion proteins. These Lm-based
strains are believed to be a significant advancement in
immunotherapy as they integrate multiple functions into a single
immunotherapy and are designed to access and direct antigen
presenting cells to stimulate anti-tumor T cell immunity, activate
the immune system with the equivalent of multiple adjuvants, and
simultaneously reduce tumor protection in the tumor
microenvironment to enable T cells to eliminate tumors. Advaxis has
four programs in various stages of clinical development: ADXS-HPV
for cervical cancer; ADXS-NEO, a personalized neoantigen-directed
therapy for multiple cancers; ADXS-503 for non-small cell lung
cancer, from its ADXS-HOT off-the-shelf neoantigen-directed
program; and ADXS-PSA for prostate cancer.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook and YouTube.
Advaxis Forward-Looking Statement
Some of the statements included in this press release may be
forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the
safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. The factors that could
cause our actual results to differ materially include: the success
and timing of our clinical trials, including subject accrual; our
ability to avoid any clinical holds; our ability to obtain and
maintain regulatory approval and/or reimbursement of our product
candidates for marketing; our ability to obtain the appropriate
labeling of our products under any regulatory approval; our plans
to develop and commercialize our products; the successful
development and implementation of our sales and marketing
campaigns; the size and growth of the potential markets for our
product candidates and our ability to serve those markets; our
ability to successfully compete in the potential markets for our
product candidates, if commercialized; regulatory developments in
the United States and other countries; the rate and degree of
market acceptance of any of our product candidates; new products,
product candidates or new uses for existing products or
technologies introduced or announced by our competitors and the
timing of these introductions or announcements; market conditions
in the pharmaceutical and biotechnology sectors; our available
cash, including to support current and planned clinical activities;
the accuracy of our estimates regarding expenses, future revenues,
capital requirements and needs for additional financing; our
ability to obtain additional funding; our ability to obtain and
maintain intellectual property protection for our product
candidates; the success and timing of our preclinical studies
including IND-enabling studies; the timing of our IND submissions;
our ability to get FDA approval for study amendments; the timing of
data read-outs; the ability of our product candidates to
successfully perform in clinical trials; our ability to initiate,
enroll, and execute pilots and clinical trials; our ability to
maintain collaborations; our ability to manufacture and the
performance of third-party manufacturers; the performance of our
clinical research organizations, clinical trial sponsors and
clinical trial investigators; our ability to successfully implement
our strategy; and, other risk factors identified from time to time
in our reports filed with the SEC. Any forward-looking
statements set forth in this press release speak only as of the
date of this press release. We do not intend to update any of these
forward-looking statements to reflect events or circumstances that
occur after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190604005048/en/
Investors:LHA Investor RelationsYvonne Briggs, (310)
691-7100ybriggs@lhai.com
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Sep 2023 to Sep 2024